Lantheus Medical Imaging has released preliminary findings from Phase III clinical trials of F-18 flurpiridaz, a PET myocardial perfusion imaging agent for detection of heart disease. According to the results, PET MPI with F-18 flurpiridaz outperformed SPECT in terms of sensitivity and diagnostic accuracy but did not meet an endpoint associated with identifying healthy subjects.

Full Story:
Business Wire

Related Summaries